AFFX Affymetrix, Inc.

TGen and Affymetrix Partner to Use GeneChip(R) DNA Analysis Products in Major Collaborative Programs Genotyping Technology that Leverages an Innovative Whole-Genome SNP Assay Is Available to Commercial and Academic Research Partners and Future Collaborators SANTA CLARA, Calif. and PHOENIX, Feb. 11 /PRNewswire-FirstCall/ -- Affymetrix, Inc. , and the Translational Genomics Research Institute (TGen) announced today that they have entered into a non-exclusive agreement under which TGen will offer genotyping services to their collaborators and NIH funded core facility programs using Affymetrix GeneChip(R) brand DNA analysis technology. TGen currently runs gene expression core facility programs on the Affymetrix platform for The National Institutes of Mental Health and the National Institutes of Neurological Disease and Stroke. As part of this agreement, these programs have been expanded to run the Affymetrix DNA analysis technologies. Affymetrix and TGen also agreed to a framework under which they will collaborate on future projects. "Affymetrix Mapping 10K Array is a powerful tool for linkage analysis and is available today," said Dietrich Stephan, Ph.D., Director of TGen's Neurogenomics Program. "We recently completed a complete linkage study and reproduced the disease causing gene in just five days using the 10K. Affymetrix' cutting edge technology helped realize our vision of rapidly translating genomic discovery." "TGen's geneticists, scientific team and one of the world's fastest super computers dedicated to the study of genetics combined with the Affymetrix SNP platform will help scientists accelerate research of complex diseases and we are thrilled to be a part of that," said Affymetrix' Chief Commercial Officer Trevor J. Nicholls, Ph.D. "The flexibility and affordability of the Mapping 10K will allow TGen to provide both large research institutions and individual researchers with the most powerful genotyping technology available today." The Mapping 10K Array meets the growingcustomer demand for powerful SNP genotyping solutions in basic research, clinical research and development, drug discovery, and pharmacogenomics. The Mapping 10K Array brings whole genome SNP analysis to the bench top by combining an innovative, scalable assay with a proven information platform -- one primer, one array, 10,000 SNPs. The Mapping 10K delivers the most markers and highest resolution available in a single experiment, making it easier to pinpoint genomic regions linked to disease. Applications include genetic linkage studies of inherited disease in families, cancer genetics, and population genetics. About Affymetrix: Affymetrix is a pioneer in creating breakthrough tools that are driving the genomic revolution. By applying the principles of semiconductor technology to the life sciences, Affymetrix develops and commercializes systems that enable scientists to improve quality of life. The Company's customers include pharmaceutical, biotechnology, agrichemical, diagnostics and consumer products companies as well as academic, government and other non-profit research institutes. Affymetrix offers an expanding portfolio of integrated products and services, including its integrated GeneChip platform, to address growing markets focused on understanding the relationship between genes and human health. Additional information on Affymetrix can be found at http://www.affymetrix.com/. About TGen: The mission of the Translational Genomics Research Institute (TGen) is to make and translate genomic discoveries into advances in human health. "Translational genomics research" is a relatively new field employing innovative advances arising from the Human Genome Project to apply to the development of diagnostics, prognostics and therapiesfor cancer, neurologic disorders, diabetes and other complex diseases. All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, includingstatements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to risks of the Company's ability to achieve and sustain higher levels of revenue, higher gross margins, reduced operating expenses, uncertainties relating to technological approaches, manufacturing, product development, market acceptance (including uncertainties relating to product development and market acceptance of the GeneChip 10K Mapping Array), personnel retention, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition, risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2002 and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix, Inc. DATASOURCE: Affymetrix, Inc. CONTACT: media, Wes Conard, Associate Director, Public Relations, +1-408-731-5791, or investors, Doug Farrell, Vice President, Investor Relations, +1-408-731-5285, both of Affymetrix, Inc. Web site: http://www.affymetrix.com/

Copyright